Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Free Cash Flow for 3 consecutive years, with -$12.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 15.58% to -$12.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$77.1 million through Dec 2025, down 38.47% year-over-year, with the annual reading at -$77.1 million for FY2025, 38.47% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$12.9 million at Artiva Biotherapeutics, up from -$19.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$10.1 million in Q4 2023, with the low at -$24.1 million in Q2 2025.
  • Average Free Cash Flow over 3 years is -$15.4 million, with a median of -$14.4 million recorded in 2024.
  • Peak annual rise in Free Cash Flow hit 15.58% in 2025, while the deepest fall reached 75.58% in 2025.
  • Over 3 years, Free Cash Flow stood at -$10.1 million in 2023, then tumbled by 51.67% to -$15.3 million in 2024, then grew by 15.58% to -$12.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$12.9 million, -$19.8 million, and -$24.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.